Table 3.
Group | Response grade | Incidence | Severity | |||||
---|---|---|---|---|---|---|---|---|
0 | 0.5 | 1 | 2 | 3 | ||||
p-Phenylenediamine | Control | 0 | 5 | 0 | 0 | 0 | 0/5 | 0.8 |
Test | 0 | 1 | 4 | 5 | 0 | 9/10 | 2.65 | |
NTXOL | Control | 5 | 0 | 0 | 0 | 0 | 0/5 | 0 |
Test | 5 | 0 | 0 | 0 | 0 | 0/5 | 0 |
Group | Response grade | Incidence | Severity | |||||
---|---|---|---|---|---|---|---|---|
0 | 0.5 | 1 | 2 | 3 | ||||
p-Phenylenediamine | Control | 0 | 5 | 0 | 0 | 0 | 0/5 | 0.8 |
Test | 0 | 1 | 4 | 5 | 0 | 9/10 | 2.65 | |
NTXOL | Control | 5 | 0 | 0 | 0 | 0 | 0/5 | 0 |
Test | 5 | 0 | 0 | 0 | 0 | 0/5 | 0 |